Shares of Endo International (NASDAQ:ENDP) rose 1.1% after the company reported Q1 results.
Earnings per share were up 79.25% year over year to $0.95, which beat the estimate of $0.53.
Revenue of $820,405,000 higher by 13.88% from the same period last year, which beat the estimate of $707,650,000.
Endo International hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: May 07, 2020
Time: 05:02 PM ET
Webcast URL: https://edge.media-server.com/mmc/p/kk3vi2nq
Company's 52-week high was at $8.55
52-week low: $1.97
Price action over last quarter: down 20.07%
After a string of acquisitions and divestitures, Endo is a specialty pharmaceutical company with a considerable presence in pain management. The acquisitions of Auxilium and Par increased the company's presence in urology and generics, respectively.